Hydrochloric Acid

Hydrochloric Acid

SCHEMBL104802

COC(=O)[C@@H](C)N.Cl

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL248769 1.00 — —
Hydrochloric Acid SCHEMBL9699743 1.00 — —
Hydrochloric Acid SCHEMBL6840677 1.00 — —
Hydrochloric Acid SCHEMBL30887880 1.00 — —
Hydrochloric Acid SCHEMBL101772 1.00 — —
SCHEMBL72838 0.97 — —
SCHEMBL41892 0.97 — —
SCHEMBL104803 0.97 — —
SCHEMBL30039818 0.97 — —
SCHEMBL25301326 0.94 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 823 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119684220-A Preparation method of (2R, 5R) -1,2, 5-trimethylpiperazine 江苏宝众宝达药业股份有限公司 2025-03-25 — — CN claimed
CN-118678843-A Method for improving performance of tin-lead mixed perovskite solar cell 上海空间电源研究所 2024-09-20 — — CN claimed
CN-115232130-B APN and AKT double-target inhibitor and preparation method and application thereof 山东大学 2024-01-12 — — CN claimed
CN-113527399-B Ginsenoside CK derivative and application thereof in preparation of antitumor drugs 陕西巨子生物技术有限公司 2023-01-31 — — CN claimed
CN-114350331-B Strong-adsorption salt-resistant plugging agent based on nano-silica and water-based drilling fluid 西南石油大学 2023-01-31 — — CN claimed
CN-115232130-A APN and AKT double-target-point inhibitor and preparation method and application thereof 山东大学 2022-10-25 — — CN claimed
CN-114350331-A Strong-adsorption salt-resistant plugging agent based on nano-silica and water-based drilling fluid 西南石油大学 2022-04-15 — — CN claimed
CN-113527399-A Ginsenoside CK derivative and application thereof in preparation of antitumor drugs 陕西巨子生物技术有限公司 2021-10-22 — — CN claimed
CN-111807983-A Cinnamic acid derivative and preparation method thereof 五邑大学 2020-10-23 — — CN claimed
CN-211274271-U Stirring mechanism for preparing D-alanine methyl ester hydrochloride 四川同晟氨基酸有限公司 2020-08-18 — — CN claimed
CN-110437097-A A kind of preparation and its application of cinnamic acid derivative UNIV WUYI 2019-11-12 — — CN claimed
CN-104876950-A Sulfur-containing thick and hetero tetracyclic azasugar derivative and preparation method and application thereof UNIV HEBEI 2015-09-02 — — CN claimed
CN-103936666-A Synthetic method of 2, 4-dioxopiperidine GANSU RES INST OF CHEMICAL INDUSTRY 2014-07-23 — — CN claimed
US-20260138984-A1 1-(5-(2-CYANOPYRIDIN-4-YL)OXAZOLE-2-CARBONYL)-4-METHYLHEXAHYDROPYRROLO[3,4-B]PYR ROLE-5(1H)-CARBONITRILE ASUSP30 INHIBITOR FOR USE IN THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION, CANCER AND FIBROSIS MISSION THERAPEUTICS LTD (GB) 2026-05-21 — — US disclosed
CN-121873002-A Synthesis method and application of (3S) -1, 3-dimethylpiperazine-2-one 上海毕得医药科技股份有限公司 2026-04-17 — — CN disclosed
US-12600711-B2 Triazacyclododecansulfonamide (TCD)-based protein secretion inhibitors KEZAR LIFE SCIENCES, INC. (US) 2026-04-14 — — US disclosed
US-4469868-A ANTIPSYCHOTIC ANGENTS WARNER-LAMBERT COMPANY (US) 1984-09-04 — — US disclosed
EP-0095289-A2 Imidazo(1,2-c)pyrazolo(3,4-e)pyrimidines and their production WARNER-LAMBERT COMPANY (US) 1983-11-30 — — EP disclosed
US-4100274-A LULIBERIN ANTAGONIST IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) 1978-07-11 — — US disclosed
US-4012367-A Anti-ulcer polypeptides containing L-aspartic acid and intermediates thereto G. D. SEARLE & CO. (US) 1977-03-15 — — US disclosed
Send feedback